|
1. A bioactivatable polypeptide drug construct comprising, in an N-to C-terminal direction (D1-D2-D3): 1) a functional moiety D1 domain (D1), 2) a bioactivatable moiety D2 domain (D2), and 3) a concealing moiety D3 domain (D3); wherein the D1 domain is an Fc domain comprising an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 156, and SEQ ID NOS: 166-168; wherein the D2 domain is an interleukin-2 (IL-2) polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 8; and wherein the D3 domain is a cognate receptor/binding partner for IL-2 comprising an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NOS: 9-10; wherein D1 is attached to D2 by a peptide linker (L1) selected from the group consisting of a protease cleavable peptide linker and a non-cleavable peptide linker; wherein D2 is attached to D3 by a peptide linker (L2) selected from the group consisting of a protease cleavable peptide linker and a non-cleavable peptide linker; and wherein D3 conceals the activity of D2 until activated.
|